Zusammenfassung
Die Tumordicke ist der wichtigste prognostische Parameter für kutane Melanome. Jedoch wäre es wünschenswert mit zusätzlichen Untersuchungen die Prognose des individuellen Patienten weiter abzusichern. Bewährt haben sich in diesem Zusammenhang in mehreren Studien Proliferationsmarker und auch Adhäsionsmoleküle sowie immunologisch relevante Moleküle wie TAP1, das in der Antigenverarbeitung benötigt wird.
Abstract
The tumor thickness is the most important prognostic parameter for cutaneous melanoma. However, additional examinations are desirable to predict the prognosis of the individual patient. In this context, proliferation markers and also adhesion molecules as well as immunological relevant molecules such as TAP1, which is involved in antigen processing, have been shown to be of prognostic relevance.
Literatur
-
1
Berwick M, Halpern A.
Melanoma epidemiology.
Curr Opin Oncol.
1997;
9
178-182
-
2
Häffner A C, Garbe C, Burg G, Buttner P, Orfanos C E, Rassner G.
The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients.
Br J Cancer.
1992;
66
856-861
-
3
Dummer R, Bösch U, Panizzon R, Bloch P H, Burg G. für die Fachkommission „Hautkrebs” .
Swiss Guidelines for the treatment and follow-up of cutaneous melanoma.
Dermatology.
2001;
203
75-80
-
4
Thorn M, Ponten F, Bergstrom R, Sparen P, Adami H O.
Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden.
J Natl Cancer Inst.
1994;
86
761-769
-
5
Karakousis C P, Driscoll D L.
Prognostic parameters in localised melanoma: gender versus anatomical location.
Eur J Cancer.
1995;
3
320-324
-
6
Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H. et al .
Primary cutaneous melanoma. Prognostic classification of anatomic location.
Cancer.
1995;
75
2492-2498
-
7
Ramsay J A, From L, Iscoe N A, Kahn H J.
MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.
J Invest Dermatol.
1995;
105
22-26
-
8
Straume O, Sviland L, Akslen L A.
Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.
Clin Cancer Res.
2000;
6
1845-1853
-
9
Korabiowska M, Brinck U, Middel P, Brinkmann U, Berger H, Radzun H J. et al .
Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance.
Anticancer Res.
2000;
20
1781-1785
-
10
Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchala A, Wasilewska A. et al .
Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study.
J Surg Oncol.
1999;
70
150-160
-
11
Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V. et al .
Prognostic immunohistochemical markers of primary human melanomas.
Br J Dermatol.
2001;
145
203-209
-
12
Boni R, Doguoglu A, Burg G, Muller B, Dummer R.
MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
J Am Acad Dermatol.
1996;
35
416-418
-
13
Sparrow L E, English D R, Taran J M, Heenan P J.
Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors.
Am J Dermatopathol.
1998;
20
12-16
-
14
Hernberg M, Turunen J P, von Boguslawsky K, Muhonen T, Pyrhonen S.
Prognostic value of biomarkers in malignant melanoma.
Melanoma Res.
1998;
8
283-291
-
15
Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Franssila K. et al .
MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma.
Oncology.
1999;
57
242-252
-
16
Gelsleichter L, Gown A M, Zarbo R J, Wang E, Coltrera M D.
p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
Mod Pathol.
1995;
8
530-535
-
17
Loggini B, Rinaldi I, Pingitore R, Cristofani R, Castagna M, Barachini P.
Immunohistochemical study of 48 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance.
Tumori.
2001;
87
179-186
-
18
Yamamoto M, Takahashi H, Saitoh K, Horikoshi T, Takahashi M.
Expression of the p53 protein in malignant melanomas as a prognostic indicator.
Arch Dermatol Res.
1995;
287
146-151
-
19
McGregor J M, Yu C C, Dublin E A, Barnes D M, Levison D A, MacDonald D M.
p53 immunoreactivity in human malignant melanoma and dysplastic naevi.
Br J Dermatol.
1993;
128
606-611
-
20
Lee C S, Pirdas A, Lee M W.
p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis.
Australas J Dermatol.
1995;
36
192-195
-
21
Karjalainen J M, Eskelinen M J, Kellokoski J K, Reinikainen M, Alhava E M, Kosma V M.
p21 (WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.
Br J Cancer.
1999;
79
895-902
-
22
Weiss J, Heine M, Korner B, Pilch H, Jung E G.
Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications.
Br J Dermatol.
1995;
133
23-31
-
23
Straume O, Akslen L A.
Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma.
Int J Cancer.
1997;
74
535-539
-
24
Fernando S S, Johnson S, Bate J.
Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody.
Pathology.
1994;
26
16-19
-
25
Mirecka J, Korabiowska M, Schauer A.
Comparative distribution of S-100 protein and antigen HMB-45 in various types of melanomas and naevi.
Pol J Pathol.
1995;
46
167-172
-
26
Hofbauer G F, Schaefer C, Noppen C, Boni R, Kamarashev J, Nestle F O. et al .
MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Am J Pathol.
1997;
151
1549-1553
-
27
Hofbauer G F, Kamarashev J, Geertsen R, Boni R, Dummer R.
Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Melanoma Res.
1998;
8
337-343
-
28
Hofbauer G F, Kamarashev J, Geertsen R, Boni R, Dummer R.
Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
J Cutan Pathol.
1998;
25
204-209
-
29
Kageshita T, Kawakami Y, Ono T.
Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients.
J Dermatol Sci.
2001;
25
36-44
-
30
Busam K J, Iversen K, Berwick M, Spagnoli G C, Old L J, Jungbluth A A.
Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Med Pathol.
2000;
13
459-465
-
31
Kamarashev J, Ferrone S, Seifert B, Boni R, Nestle F O, Burg G. et al .
TAPI down-regulation in primary melanoma lesions: an independent marker of poor prognosis.
Int J Cancer.
2001;
95
23-28
-
32
Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V. et al .
Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?.
Cancer.
1999;
85
2391-2399
-
33
Townsend S E, Allison J P.
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.
Science.
1993;
259
368-370
-
34
Natali P G, Hamby C V, Felding-Habermann B, Liang B, Nicotra M R, DiFilippo F. et al .
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.
Cancer Res.
1997;
57
1554-1560
-
35
Schadendorf D, Heidel J, Gawlik C, Suter L, Czarnetzki B M.
Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels.
J Natl Cancer Inst.
1995;
87
366-371
-
36
Natali P, Nicotra M R, Cavaliere R, Bigotti A, Romano G, Temponi M. et al .
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions.
Cancer Res.
1990;
50
1271-1278
-
37
Becker J C, Dummer R, Burg G, Schmidt R E.
Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and TNF-alpha: Functional consequences on cell mediated cytotoxicity.
J Immunol.
1991;
147
4398-4401
-
38
Ciotti P, Pesce G P, Cafiero F, Rainero M L, Sementa A, Nicolo G. et al .
Intercellular adhesion molecule-1 (ICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) co-expression in cutaneous malignant melanoma lesions.
Melanoma Res.
1999;
9
253-260
-
39
Podhajcer O L, Bover L, Bravo A I, Ledda M F, Kairiyama C, Calb I. et al .
Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi.
J Invest Dermatol.
1995;
104
340-344
-
40
Goldmann T, Ribbert D, Suter L, Brode M, Otto F.
Tumor characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics.
J Exp Clin Cancer Res.
1998;
17
483-489
-
41
Vaisanen A, Kallioinen M, Taskinen P J, Turpeenniemi-Hujanen T.
Prognostic value of MMP-2 immunoreactive protein (72kD type IV collagenase) in primary skin melanoma.
J Pathol.
1998;
186
51-58
-
42
Massi D, Franchi A, Borgognoni L, Reali U M, Santucci M.
Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas.
Hum Pathol.
1999;
30
339-344
Prof. Dr. med. Reinhard Dummer
Dermatologische Klinik · Universitäts-Spital Zürich
Gloriastraße 31 · 8091 Zürich · Schweiz
Email: reinhard.dummer@der.usz.ch
